Comparative ovarian response in IUI to 5 or 7.5 mg doses of letrozole

Comparative ovarian response to 5 or 7.5 mg doses of letrozole in IUI cycle

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20140224016705N10

Enrollment

240

Registered

2020-04-07

Start date

2019-11-30

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility. Encounter for male factor infertility in female patient

Interventions

Intervention 1: Intervention group: Letrozole 7.5 mg by the patient . Letrox 2.5 mg drug Aboureihan Pharmacy was administered for 5 days from the third day of menstruation and the patient was referre

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Patients undergoing IUI at Mahdieh Infertility Center who are younger than 40 years FSH<10 with at least one fallopian tube open infertility duration of more than one year

Exclusion criteria

Exclusion criteria: Unable to track people Dissatisfaction with participation and continued study The incidence of drug side effects

Design outcomes

Primary

Measure	Time frame
Rate of fertility. Timepoint: After beginning of study. Method of measurement: Determination of beta-HCG level by blood test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public Contact?Dr. Zahra Heydar

Shahid Beheshti University of Medical Sciences

Z.heydar@sbmu.ac.ir+98 21 2387 2206

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026